83
Participants
Start Date
July 31, 2013
Primary Completion Date
May 31, 2019
Study Completion Date
June 30, 2019
CBL0137
"All doses are administered intravenously on Days 1, 8 and 15 of every 28 day cycle.~Number of Cycles: 2 or until progression or unacceptable toxicity develops"
Roswell Park Cancer Institute, Buffalo
University Hospital of Cleveland, Cleveland
Cleveland Clinic, Cleveland
CTRC at The University of Texas Healh Science Center at San Antonio, San Antonio
Lead Sponsor
Incuron
INDUSTRY